Fmr LLC Has $92,000 Stake in Invesco Pharmaceuticals ETF (NYSEARCA:PJP)

Fmr LLC grew its holdings in shares of Invesco Pharmaceuticals ETF (NYSEARCA:PJP) by 29.4% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,057 shares of the company’s stock after purchasing an additional 240 shares during the period. Fmr LLC’s holdings in Invesco Pharmaceuticals ETF were worth $92,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the business. Howe & Rusling Inc. bought a new stake in Invesco Pharmaceuticals ETF during the third quarter worth about $48,000. International Assets Investment Management LLC acquired a new stake in shares of Invesco Pharmaceuticals ETF during the 2nd quarter worth approximately $66,000. Joseph Group Capital Management increased its stake in Invesco Pharmaceuticals ETF by 10.8% in the second quarter. Joseph Group Capital Management now owns 13,001 shares of the company’s stock valued at $1,069,000 after acquiring an additional 1,272 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its position in Invesco Pharmaceuticals ETF by 49.7% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 6,826 shares of the company’s stock valued at $561,000 after purchasing an additional 2,266 shares in the last quarter. Finally, Secure Asset Management LLC bought a new stake in Invesco Pharmaceuticals ETF during the third quarter worth $229,000.

Invesco Pharmaceuticals ETF Stock Performance

Shares of PJP opened at $83.16 on Tuesday. Invesco Pharmaceuticals ETF has a 52-week low of $74.82 and a 52-week high of $89.87. The firm has a market cap of $281.91 million, a price-to-earnings ratio of 21.48 and a beta of 0.61. The business’s fifty day moving average is $86.32 and its 200-day moving average is $85.47.

Invesco Pharmaceuticals ETF Profile

PowerShares Dynamic Pharmaceuticals Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Pharmaceuticals Intellidex Index (the Index). The Index evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.